Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetShares RepurchasedWages, Salaries and Other
Ratios

BridgeBio Pharma (BBIO) Leases (2020 - 2025)

BridgeBio Pharma (BBIO) has disclosed Leases for 6 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Leases rose 41.3% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Dec 2025, up 41.3% year-over-year, with the annual reading at $8.1 million for FY2025, 41.3% up from the prior year.
  • Leases hit $8.1 million in Q4 2025 for BridgeBio Pharma, up from $6.6 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $17.1 million in Q3 2021 to a low of $5.8 million in Q4 2024.
  • Historically, Leases has averaged $10.2 million across 5 years, with a median of $9.6 million in 2023.
  • Biggest five-year swings in Leases: soared 77.4% in 2021 and later plummeted 32.87% in 2022.
  • Year by year, Leases stood at $15.9 million in 2021, then tumbled by 32.87% to $10.7 million in 2022, then decreased by 24.83% to $8.0 million in 2023, then dropped by 28.15% to $5.8 million in 2024, then surged by 41.3% to $8.1 million in 2025.
  • Business Quant data shows Leases for BBIO at $8.1 million in Q4 2025, $6.6 million in Q3 2025, and $6.2 million in Q2 2025.